Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Dechra Pharmaceuticals PLC - veterinary drug maker - Says private equity takeover approved at court and general meeting. Dechra says holders of 99% of scheme shares voted in favour at a court meeting. At a general meeting, 99% also backed it. Dechra in June agreed to a downwardly adjusted takeover by EQT AB, which is a Swedish private equity firm, and Luxinva SA, which is controlled by the sovereign wealth fund of the United Arab Emirates. The offer values Dechra at £4.46 billion on a fully-diluted basis and gives an enterprise value of £4.88 billion.
Current stock price: 3,716.00 pence
12-month change: up 2.7%
Copyright 2023 Alliance News Ltd. All Rights Reserved.